Assessment of effect of levamisole on pneumonia caused by COVID-19
Phase 4
Recruiting
- Conditions
- Coronavirus infection.Coronavirus infection, unspecifiedB34.2
- Registration Number
- IRCT20131215015805N2
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
COVID-19 Patients
moderate Lung Complication
informed consent
Exclusion Criteria
Patients with WBC COUNT <6000
Platelet less than 100 thousand
Patients with immune diseases
Previous respiratory diseases
Cancer
Pregnancy
Breast Feeding
immunosuppressive medication
organ transplant
autoimmune disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prevent the development of pneumonia caused by Convid19. Timepoint: one week. Method of measurement: CT scan.;Reduce the need for hospitalization. Timepoint: two week. Method of measurement: Measure the length of hospital stay.;Death. Timepoint: 2 to 3 week. Method of measurement: Measuring mortality.
- Secondary Outcome Measures
Name Time Method